{"id":58761,"date":"2026-02-26T12:33:53","date_gmt":"2026-02-26T12:33:53","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/car-t-cell-therapy-mordor\/"},"modified":"2026-09-18T12:51:45","modified_gmt":"2026-09-18T03:51:45","slug":"car-t-cell-therapy-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/car-t-cell-therapy-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 CAR T\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d: \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026-2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/car-t-cell-therapy_1675609461788_t_cel.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/car-t-cell-therapy-size-image-1770992905410.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 2\ucc28 LBCL FDA \uc2b9\uc778\uc73c\ub85c \ucd08\uae30 \uce58\ub8cc \ucc44\ud0dd \uac00\uc18d\ud654<\/li>\n<li class=\"toc-level-3\">4.2.2 \ubd84\uc0b0\ud615 EU \ud604\uc7a5 \uc9c4\ub8cc \uc81c\uc870\ub85c \uc815\ub9e5-\uc815\ub9e5 \uc2dc\uac04 \ub2e8\ucd95<\/li>\n<li class=\"toc-level-3\">4.2.3 \uc804 \uc138\uacc4 \uc554 \ubd80\ub2f4 \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.4 \ub3d9\uc885\uc720\ub798 &#8220;\uae30\uc131\ud488&#8221; \ud30c\uc774\ud504\ub77c\uc778\uc73c\ub85c \uc6d0\uac00 \uc808\uac10<\/li>\n<li class=\"toc-level-3\">4.2.5 CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc744 \uc704\ud55c \ud22c\uc790 \ubc0f \uc5f0\uad6c \uac1c\ubc1c \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.6 \uc9c0\uc5ed \uc885\uc591\ud559 \uc13c\ud130\ub85c\uc758 Medicare NTAP \ud655\uc7a5\uc73c\ub85c \uc811\uadfc\uc131 \ud655\ub300<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d\n<ul>\n<li class=\"toc-level-3\">4.3.1 CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc758 \ub192\uc740 \ube44\uc6a9<\/li>\n<li class=\"toc-level-3\">4.3.2 \ubca1\ud130 GMP \uc6a9\ub7c9 \ubcd1\ubaa9 \ud604\uc0c1\uc73c\ub85c \ub9ac\ub4dc \ud0c0\uc784 \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.3.3 \uc81c\ud55c\ub41c \ud658\uc790 \uc801\uaca9\uc131<\/li>\n<li class=\"toc-level-3\">4.3.4 \uc2ec\uac01\ud55c \ubd80\uc791\uc6a9 \uac00\ub2a5\uc131<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uacf5\uae09\ub9dd \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">4.5 \uaddc\uc81c \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.6 \uae30\uc220 \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.7 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.7.1 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.2 \uacf5\uae09\uc5c5\uccb4\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.3 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58, USD)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \ud45c\uc801 \ud56d\uc6d0\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.1.1 CD19<\/li>\n<li class=\"toc-level-3\">5.1.2 BCMA<\/li>\n<li class=\"toc-level-3\">5.1.3 CD22<\/li>\n<li class=\"toc-level-3\">5.1.4 GD2<\/li>\n<li class=\"toc-level-3\">5.1.5 HER2<\/li>\n<li class=\"toc-level-3\">5.1.6 PSMA<\/li>\n<li class=\"toc-level-3\">5.1.7 \ub2e4\uc911 \ud45c\uc801 \/ \ud0e0\ub364<\/li>\n<li class=\"toc-level-3\">5.1.8 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 \uc790\uac00<\/li>\n<li class=\"toc-level-3\">5.2.2 \ub3d9\uc885<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uc81c\ud488\ubcc4 (\uc2b9\uc778\ub428)\n<ul>\n<li class=\"toc-level-3\">5.3.1 \uc544\ubca1\ub9c8<\/li>\n<li class=\"toc-level-3\">5.3.2 \ube0c\ub808\uc580\uc9c0<\/li>\n<li class=\"toc-level-3\">5.3.3 \ud0b4\ub9ac\uc544<\/li>\n<li class=\"toc-level-3\">5.3.4 \ud14c\uce74\ub974\ud22c\uc2a4<\/li>\n<li class=\"toc-level-3\">5.3.5 \uc608\uc2a4\uce74\ub974\ud0c0<\/li>\n<li class=\"toc-level-3\">5.3.6 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \uc801\uc751\uc99d\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 \ubc31\ud608\ubcd1 (ALL, CLL)<\/li>\n<li class=\"toc-level-3\">5.4.2 \ub9bc\ud504\uc885 (DLBCL &amp; \uae30\ud0c0 B\uc138\ud3ec)<\/li>\n<li class=\"toc-level-3\">5.4.3 \ub2e4\ubc1c\uc131 \uace8\uc218\uc885<\/li>\n<li class=\"toc-level-3\">5.4.4 \uc790\uac00\uba74\uc5ed \uc9c8\ud658<\/li>\n<li class=\"toc-level-3\">5.4.5 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.5 \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.5.1 \ubcd1\uc6d0<\/li>\n<li class=\"toc-level-3\">5.5.2 \uc554 \uce58\ub8cc \uc13c\ud130<\/li>\n<li class=\"toc-level-3\">5.5.3 \ud559\uc220 \ubc0f \uc5f0\uad6c \uae30\uad00<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.6 \uc9c0\uc5ed\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.6.1 \ubd81\ubbf8\n<ul>\n<li class=\"toc-level-4\">5.6.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.6.1.3 \uba55\uc2dc\ucf54<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.2 \uc720\ub7fd\n<ul>\n<li class=\"toc-level-4\">5.6.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.6.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.6.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.6.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.6.2.6 \uae30\ud0c0 \uc720\ub7fd<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\n<ul>\n<li class=\"toc-level-4\">5.6.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.2 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.6.3.3 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.6.3.4 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.5 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.6.3.6 \uae30\ud0c0 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.4 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74\n<ul>\n<li class=\"toc-level-4\">5.6.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.6.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.6.4.3 \uae30\ud0c0 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.5 \ub0a8\ubbf8\n<ul>\n<li class=\"toc-level-4\">5.6.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.6.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.6.5.3 \uae30\ud0c0 \ub0a8\ubbf8<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uc218\uc900 \uac1c\uc694, \uc2dc\uc7a5 \uc218\uc900 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34, \uc804\ub7b5 \uc815\ubcf4, \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uadfc \uac1c\ubc1c \ud3ec\ud568)\n<ul>\n<li class=\"toc-level-3\">6.3.1 Novartis AG<\/li>\n<li class=\"toc-level-3\">6.3.2 Gilead Sciences Inc. (Kite Pharma)<\/li>\n<li class=\"toc-level-3\">6.3.3 Bristol-Myers Squibb Co.<\/li>\n<li class=\"toc-level-3\">6.3.4 Johnson &amp; Johnson \/ Legend Biotech<\/li>\n<li class=\"toc-level-3\">6.3.5 2seventy bio Inc.<\/li>\n<li class=\"toc-level-3\">6.3.6 Allogene Therapeutics Inc.<\/li>\n<li class=\"toc-level-3\">6.3.7 Autolus Therapeutics plc<\/li>\n<li class=\"toc-level-3\">6.3.8 Caribou Biosciences Inc.<\/li>\n<li class=\"toc-level-3\">6.3.9 TCR\u00b2 Therapeutics Inc.<\/li>\n<li class=\"toc-level-3\">6.3.10 Precision BioSciences Inc.<\/li>\n<li class=\"toc-level-3\">6.3.11 Sorrento Therapeutics Inc.<\/li>\n<li class=\"toc-level-3\">6.3.12 Sangamo Therapeutics Inc.<\/li>\n<li class=\"toc-level-3\">6.3.13 Celyad Oncology SA<\/li>\n<li class=\"toc-level-3\">6.3.14 Servier Laboratories<\/li>\n<li class=\"toc-level-3\">6.3.15 Miltenyi Biotec B.V. &amp; Co.<\/li>\n<li class=\"toc-level-3\">6.3.16 ACROBiosystems<\/li>\n<li class=\"toc-level-3\">6.3.17 JW Therapeutics<\/li>\n<li class=\"toc-level-3\">6.3.18 Fosun Kite Biotechnology Co.<\/li>\n<li class=\"toc-level-3\">6.3.19 Beigene Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.20 Gracell Biotechnologies Ltd.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5 \uac1c\uc694 (2026-2031\ub144)<\/p>\n<p>\uae00\ub85c\ubc8c CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2025\ub144 42\uc5b5 \ub2ec\ub7ec\uc5d0\uc11c 2026\ub144 47.7\uc5b5 \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud588\uc73c\uba70, 2031\ub144\uc5d0\ub294 90.3\uc5b5 \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc608\uce21 \uae30\uac04(2026-2031\ub144) \ub3d9\uc548 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR)\uc740 13.63%\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \ubd81\ubbf8 \uc9c0\uc5ed\uc774 \uac00\uc7a5 \ud070 \uc2dc\uc7a5\uc744 \ud615\uc131\ud558\uace0 \uc788\uc73c\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5\uc73c\ub85c \ubd80\uc0c1\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud604\uc7ac \uc2dc\uc7a5 \uc9d1\uc911\ub3c4\ub294 \uc911\uac04 \uc218\uc900\uc785\ub2c8\ub2e4.<\/p>\n<p># \uc2dc\uc7a5 \uc131\uc7a5 \ub3d9\uc778 \ubc0f \ud2b8\ub80c\ub4dc<\/p>\n<p>CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uacac\uc778\ud558\ub294 \uc8fc\uc694 \uc694\uc778\ub4e4\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4.<\/p>\n<p>1.  \uc870\uae30 \uce58\ub8cc \ub77c\uc778\uc73c\ub85c\uc758 FDA \uc2b9\uc778 \ud655\ub300: \uaddc\uc81c \ub2f9\uad6d\uc774 CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c\uc758 \uc870\uae30 \uce58\ub8cc \ub77c\uc778 \uc0ac\uc6a9\uc744 \ud5c8\uc6a9\ud558\uba74\uc11c \uc2dc\uc7a5 \ucc44\ud0dd\uc774 \uac00\uc18d\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud2b9\ud788 2024\ub144 4\uc6d4 FDA\uac00 \uc544\ubca0\ud06c\ub9c8(Abecma)\ub97c 2\ucc28 \uce58\ub8cc\uc81c\ub85c \uc2b9\uc778\ud55c \uc0ac\ub840\ub294 \uce58\ub8cc \ub300\uc0c1 \ud658\uc790\uad70\uc744 \ud06c\uac8c \ud655\ub300\ud588\uc2b5\ub2c8\ub2e4. \ube0c\ub808\uc580\uc9c0(Breyanzi)\uc758 2\ucc28 LBCL(\ub300\ud615 B\uc138\ud3ec \ub9bc\ud504\uc885) \uc784\uc0c1 3\uc0c1 TRANSFORM \ub370\uc774\ud130\ub294 \ud654\ud559\uc694\ubc95 \ub300\ube44 45.8% \ub300 19.1%\ub77c\ub294 \uc6b0\uc218\ud55c 3\ub144 \ubb34\uc0ac\uac74 \uc0dd\uc874\uc728\uc744 \ubcf4\uc5ec\uc8fc\uba70, \uc885\uc591 \uc804\ubb38\uc758\ub4e4\uc774 CAR T \uce58\ub8cc\ub97c \ub354 \uc77c\ucc0d \uc801\uc6a9\ud558\ub3c4\ub85d \uc720\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub294 \uc7ac\ubc1c \uac10\uc18c\ub85c \uc778\ud55c \uc7a5\uae30\uc801\uc778 \ube44\uc6a9 \uc0c1\uc1c4 \uac00\ub2a5\uc131\uc744 \uc81c\uc2dc\ud558\uba70, \uc2dc\uc7a5\uc758 \ub450 \uc790\ub9bf\uc218 \uc131\uc7a5\uc744 \ub4b7\ubc1b\uce68\ud569\ub2c8\ub2e4.<br \/>\n2.  \uc720\ub7fd\uc758 \ubd84\uc0b0\ud615 \ud604\uc7a5 \uc81c\uc870(Point-of-Care Manufacturing) \ud5c8\ube0c: \uc720\ub7fd\uc5d0\uc11c\ub294 \ud604\uc7a5 \uc81c\uc870 \ud5c8\ube0c\ub97c \ud1b5\ud574 &#8216;\uc815\ub9e5\uc5d0\uc11c \uc815\ub9e5\uae4c\uc9c0(vein-to-vein)&#8217; \ucc98\ub9ac \uc2dc\uac04\uc744 \uc57d 1\uc8fc\uc77c\ub85c \ub2e8\ucd95\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. Euplagia-1 \uc784\uc0c1\uc2dc\ud5d8\uc5d0\uc11c \uc7ac\ubc1c\uc131 CLL\/SLL \ud658\uc790\uc5d0\uac8c 7\uc77c \ud604\uc7a5 \uc81c\uc870 \uacf5\uc815\uc744 \uc801\uc6a9\ud558\uc5ec 92%\uc758 \uc804\uccb4 \ubc18\uc751\ub960\uacfc 75%\uc758 \uc644\uc804 \ubc18\uc751\ub960\uc744 \ub2ec\uc131\ud588\uc2b5\ub2c8\ub2e4. \uc774\ub294 \ube60\ub974\uac8c \uc9c4\ud589\ub418\ub294 \uc554 \ud658\uc790\uc758 \uce58\ub8cc \uc911\ub2e8\uc728\uc744 \uc904\uc774\uace0, \ub300\uaddc\ubaa8 \uc790\ubcf8 \ud22c\uc790 \uc5c6\uc774\ub3c4 \uce58\ub8cc \uc13c\ud130\uc758 \uc5ed\ub7c9\uc744 \ub192\uc774\ub294 \ud6a8\uacfc\uac00 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n3.  \uc804 \uc138\uacc4 \uc554 \ubd80\ub2f4 \uc99d\uac00: \uc804 \uc138\uacc4\uc801\uc73c\ub85c \uc554 \ubc1c\ubcd1\ub960\uacfc \uc870\uae30 \uc9c4\ub2e8\uc774 \uc99d\uac00\ud558\uba74\uc11c 1,200\uac1c \uc774\uc0c1\uc758 \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c \ud6c4\ubcf4 \ubb3c\uc9c8\uc774 \uc784\uc0c1 \uc5f0\uad6c \ub2e8\uacc4\uc5d0 \uc788\uc2b5\ub2c8\ub2e4. \uace0\ub839\ud654 \uc778\uad6c\uc640 \uc0dd\ud65c \uc2b5\uad00 \ubcc0\ud654\ub294 \ud608\uc561\uc554 \ud658\uc790 \uc218\ub97c \uc99d\uac00\uc2dc\ucf1c \ud601\uc2e0\uc801\uc778 \uba74\uc5ed \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uc218\uc694\ub97c \ucd09\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc911\uad6d, \ud55c\uad6d, \uc2f1\uac00\ud3ec\ub974 \uc815\ubd80\ub294 \uace0\uac00\uc758 \uc218\uc785\ud488\uc744 \uc904\uc774\uae30 \uc704\ud574 \uad6d\ub0b4 \uc81c\uc870\ub97c \uc9c0\uc6d0\ud558\uba70, \uc774\ub294 \ubcf4\ud5d8 \uc801\uc6a9 \ud655\ub300\ub85c \uc774\uc5b4\uc9c0\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n4.  \ub3d9\uc885\uc720\ub798(Allogeneic) &#8220;\uae30\uc131\ud488(Off-the-Shelf)&#8221; \ud30c\uc774\ud504\ub77c\uc778\uc758 \ube44\uc6a9 \uc808\uac10: \ub3d9\uc885\uc720\ub798 CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c\ub294 \uc790\uac00\uc720\ub798(Autologous) \uce58\ub8cc\uc81c \ub300\ube44 \uc57d 95%\uc758 \uc6a9\ub7c9\ub2f9 \ube44\uc6a9 \uc808\uac10 \ud6a8\uacfc(\uc790\uac00\uc720\ub798 95,780\ub2ec\ub7ec vs \ub3d9\uc885\uc720\ub798 4,460\ub2ec\ub7ec)\ub97c \uc81c\uacf5\ud558\uc5ec \ube44\uc6a9 \ud6a8\uc728\uc131\uc744 \uc911\uc2dc\ud558\ub294 \ubcf4\ud5d8\uc0ac\ub4e4\uc5d0\uac8c \ub9e4\ub825\uc801\uc785\ub2c8\ub2e4. \uc989\uac01\uc801\uc778 \uc0ac\uc6a9 \uac00\ub2a5\uc131\uc740 \uacf5\uaca9\uc801\uc778 \uc9c8\ubcd1 \uce58\ub8cc\uc640 \ud608\uc561 \uc131\ubd84 \ucc44\uc9d1 \uc2dc\uc124\uc774 \ubd80\uc871\ud55c \uc9c0\uc5ed\uc5d0\uc11c \uc911\uc694\ud569\ub2c8\ub2e4.<br \/>\n5.  CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc744 \uc704\ud55c \ud22c\uc790 \ubc0f R&#038;D \uc99d\uac00: \ubd81\ubbf8\uc640 \uc720\ub7fd\uc744 \uc911\uc2ec\uc73c\ub85c CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc5d0 \ub300\ud55c \ud22c\uc790\uc640 \uc5f0\uad6c \uac1c\ubc1c\uc774 \ud65c\ubc1c\ud558\uba70, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\ub3c4 \ubd80\uc0c1\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n6.  \ubbf8\uad6d \uba54\ub514\ucf00\uc5b4 NTAP(New Technology Add-on Payment) \ud655\ub300: \uba54\ub514\ucf00\uc5b4 NTAP\uac00 \uc9c0\uc5ed \uc885\uc591 \uce58\ub8cc \uc13c\ud130\ub85c \ud655\ub300\ub418\uba74\uc11c CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c\uc5d0 \ub300\ud55c \uc811\uadfc\uc131\uc774 \ud5a5\uc0c1\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p># \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778<\/p>\n<p>\uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc8fc\uc694 \uc81c\uc57d \uc694\uc778\ub4e4\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4.<\/p>\n<p>1.  \ub192\uc740 \uac1c\ubc1c \ube44\uc6a9: \uc790\uac00\uc720\ub798 CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c\ub294 200\uc2dc\uac04 \uc774\uc0c1\uc758 \ub178\ub3d9 \uc2dc\uac04\uc774 \ud544\uc694\ud558\uba70, \uc815\uac00 50\ub9cc \ub2ec\ub7ec \uc774\uc0c1\uc73c\ub85c \ucc45\uc815\ub418\uc5b4 \uace0\uc18c\ub4dd \uad6d\uac00\uc758 \uc758\ub8cc \uc2dc\uc2a4\ud15c\uc5d0\uc11c\ub9cc \ucc44\ud0dd\uc774 \uc81c\ud55c\ub429\ub2c8\ub2e4. \ub77c\ud2f4 \uc544\uba54\ub9ac\uce74, \uc911\ub3d9 \ubc0f \ub3d9\uc720\ub7fd \uc77c\ubd80 \uc9c0\uc5ed\uc758 \ud30c\ud3b8\ud654\ub41c \ubcf4\ud5d8 \uc2dc\uc2a4\ud15c\uc740 \ub9ce\uc740 \uc801\uaca9 \ud658\uc790\ub4e4\uc774 \uce58\ub8cc\ub97c \ubc1b\uc9c0 \ubabb\ud558\uac8c \ud569\ub2c8\ub2e4.<br \/>\n2.  \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 GMP \uc0dd\uc0b0 \ub2a5\ub825 \ubcd1\ubaa9 \ud604\uc0c1: \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4(lentiviral) \uc0dd\uc0b0 \uc2ac\ub86f \ubd80\uc871\uc740 \uc0c1\uc5c5\uc6a9 \ubc30\uce58 \ubc0f \uc8fc\uc694 \uc784\uc0c1 \uc2dc\ud5d8\uc744 \uc9c0\uc5f0\uc2dc\ud0a4\uace0, \ub9ac\ub4dc \ud0c0\uc784\uc744 \ub298\ub9ac\uba70, \uc0dd\uc0b0\ub7c9 \uc99d\uac00\ub97c \uc81c\ud55c\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc0dd\uc0b0 \ub2a5\ub825 \ud655\uc7a5\uc740 \uc790\ubcf8 \uc9d1\uc57d\uc801\uc774\uba70 \ucd5c\ub300 2\ub144\uc774 \uc18c\uc694\ub429\ub2c8\ub2e4.<br \/>\n3.  \uc81c\ud55c\ub41c \ud658\uc790 \uc801\uaca9\uc131: CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c\ub294 \uc804 \uc138\uacc4\uc801\uc73c\ub85c, \ud2b9\ud788 \uace0\ub839 \uc778\uad6c\uc5d0\uc11c \ud658\uc790 \uc801\uaca9\uc131\uc774 \uc81c\ud55c\uc801\uc785\ub2c8\ub2e4.<br \/>\n4.  \uc2ec\uac01\ud55c \ubd80\uc791\uc6a9 \uac00\ub2a5\uc131: \uc0ac\uc774\ud1a0\uce74\uc778 \ubc29\ucd9c \uc99d\ud6c4\uad70(CRS) \ubc0f \uc2e0\uacbd\ub3c5\uc131(ICANS)\uacfc \uac19\uc740 \uc2ec\uac01\ud55c \ubd80\uc791\uc6a9 \ubc1c\uc0dd \uac00\ub2a5\uc131\uc740 \uc804 \uc138\uacc4\uc801\uc73c\ub85c, \ud2b9\ud788 \uc720\ub7fd\uacfc \ubbf8\uad6d\uc5d0\uc11c \uaddc\uc81c \ub2f9\uad6d\uc758 \uc8fc\uc694 \uad00\uc2ec\uc0ac\uc785\ub2c8\ub2e4.<\/p>\n<p># \uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d<\/p>\n<p>1. \ud45c\uc801 \ud56d\uc6d0(Target Antigen):<br \/>\nCD19 \ud50c\ub7ab\ud3fc\uc740 2025\ub144 CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5 \ub9e4\ucd9c\uc758 46.05%\ub97c \ucc28\uc9c0\ud558\uba70, \ubbf8\ub9cc\uc131 \uac70\ub300 B\uc138\ud3ec \ub9bc\ud504\uc885(DLBCL) \ubc0f \uc18c\uc544 \uae09\uc131 \ub9bc\ud504\uad6c\uc131 \ubc31\ud608\ubcd1(ALL)\uc5d0 \ub300\ud55c \ucd08\uae30 \uc2b9\uc778\uc744 \ubc14\ud0d5\uc73c\ub85c \uc120\ub450\ub97c \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. BCMA \ud45c\uc801 \uce58\ub8cc\uc81c\ub294 \uc544\ubca0\ud06c\ub9c8\uc758 \uc870\uae30 \uce58\ub8cc \ub77c\uc778 \uc2b9\uc778\uc5d0 \ud798\uc785\uc5b4 2031\ub144\uae4c\uc9c0 14.02%\uc758 \uac00\uc7a5 \ube60\ub978 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. CD19\uc640 CD20 \ub610\ub294 CD22\ub97c \uacb0\ud569\ud55c \uc774\uc911 \ud45c\uc801 \ud504\ub85c\uadf8\ub7a8\uc740 \ud56d\uc6d0 \ud68c\ud53c\ub97c \uadf9\ubcf5\ud558\uae30 \uc704\ud574 \uc911\uae30 \uc784\uc0c1 \uc2dc\ud5d8\uc5d0 \uc9c4\uc785\ud558\uace0 \uc788\uc73c\uba70, \ud608\uc561\uc554\uc744 \ub118\uc5b4 \uace0\ud615\uc554(\uc2e0\uacbd\ubaa8\uc138\ud3ec\uc885\uc758 GD2, \uc704\uc554\uc758 HER2 \ubc0f CLDN18.2)\uc73c\ub85c\uc758 \ucc28\uc138\ub300 \ud56d\uc6d0 \uc804\ub7b5\uc774 \ubaa8\uc0c9\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>2. \uc138\ud3ec \uacf5\uae09\uc6d0(Cell Source):<br \/>\n\uc790\uac00\uc720\ub798(Autologous) \uce58\ub8cc\uc81c\ub294 2025\ub144 \ub9e4\ucd9c\uc758 91.25%\ub97c \ucc28\uc9c0\ud558\uba70 \ud604\uc7ac \uc2dc\uc7a5\uc758 \uc911\ucd94 \uc5ed\ud560\uc744 \ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 2~4\uc8fc\uc758 &#8216;\uc815\ub9e5\uc5d0\uc11c \uc815\ub9e5\uae4c\uc9c0&#8217; \uc2dc\uac04\uacfc \uac00\ubcc0\uc801\uc778 \uc81c\ud488 \ud488\uc9c8\uc740 \uace0\ub4f1\uae09 \ub9bc\ud504\uc885\uc5d0\uc11c \uc7a5\uc560\ubb3c\ub85c \uc791\uc6a9\ud569\ub2c8\ub2e4. \ub3d9\uc885\uc720\ub798(Allogeneic) \ud504\ub85c\uc81d\ud2b8\ub294 15.22%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub418\uba70, \ubc30\uce58 \uc0dd\uc0b0, \ub0ae\uc740 \uc81c\uc870 \ube44\uc6a9, \uc989\uac01\uc801\uc778 \ud22c\uc5ec \uac00\ub2a5\uc131 \ub4f1\uc758 \uc7a5\uc810\uc73c\ub85c \uc8fc\ubaa9\ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc54c\ub85c\uc820(Allogene) \ub4f1\uc740 \uc720\uc804\uc790 \ud3b8\uc9d1 \ub3c4\uad6c\ub97c \uc0ac\uc6a9\ud558\uc5ec \uacf5\uc5ec\uc790 \uc138\ud3ec\ub97c \uc219\uc8fc \uba74\uc5ed\uc73c\ub85c\ubd80\ud130 \ubcf4\ud638\ud558\uace0 \uc790\uac00\uc720\ub798 \uce58\ub8cc\uc81c\uc640 \uc720\uc0ac\ud55c \uc9c0\uc18d\uc131\uc744 \ubaa9\ud45c\ub85c \ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>3. \uc81c\ud488(Product):<br \/>\n\uae38\ub9ac\uc5b4\ub4dc(Gilead)\uc758 \uc608\uc2a4\uce74\ub974\ud0c0(Yescarta)\ub294 \uc131\uc778 LBCL \ubc0f \uc5ec\ud3ec\uc131 \ub9bc\ud504\uc885 \uc801\uc751\uc99d\uacfc CNS \ub9bc\ud504\uc885\uc5d0\uc11c 66.7%\uc758 \uc644\uc804 \ubc18\uc751\ub960\uc744 \ubcf4\uc774\ub294 \uac15\ub825\ud55c \uc2e4\uc81c \ub370\uc774\ud130\uc5d0 \ud798\uc785\uc5b4 2025\ub144 \uc804 \uc138\uacc4 \ub9e4\ucd9c\uc758 37.35%\ub97c \uae30\ub85d\ud588\uc2b5\ub2c8\ub2e4. \uc544\ubca0\ud06c\ub9c8(Abecma)\ub294 2\ucc28 \uce58\ub8cc \ub77c\uc778 \ub2e4\ubc1c\uc131 \uace8\uc218\uc885\uc5d0 \uc0c8\ub85c \uc2b9\uc778\ub418\uc5b4 2031\ub144\uae4c\uc9c0 14.68%\uc758 \uac00\uc7a5 \ub192\uc740 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uacbd\uc7c1\uc740 \uc81c\uc870 \uc5ed\ub7c9\uc73c\ub85c \uc804\ud658\ub418\uace0 \uc788\uc73c\uba70, \uce74\uc774\ud2b8(Kite)\ub294 2026\ub144\uae4c\uc9c0 \uc138\ud3ec \ucc98\ub9ac\ub7c9\uc744 4\ubc30 \ub298\ub9b4 \uacc4\ud68d\uc774\uba70, \ube0c\ub9ac\uc2a4\ud1a8-\ub9c8\uc774\uc5b4\uc2a4 \uc2a4\ud045(Bristol-Myers Squibb)\uc740 \uc790\ub3d9\ud654\ub41c \ud3d0\uc1c4 \uc2dc\uc2a4\ud15c\uc744 \uc2dc\ud5d8 \uc6b4\uc601\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>4. \uc801\uc751\uc99d(Indication):<br \/>\n\ub9bc\ud504\uc885 \uc801\uc751\uc99d\uc740 2025\ub144 \ub9e4\ucd9c\uc758 54.05%\ub97c \ucc28\uc9c0\ud558\uba70, \uc131\uc219\ud55c \ubcf4\ud5d8 \uc801\uc6a9\uacfc \uad11\ubc94\uc704\ud55c \uc801\uc751\uc99d \ubc94\uc704\uc5d0 \ud798\uc785\uc5b4 \uc9c0\ubc30\uc801\uc778 \uc704\uce58\ub97c \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub2e4\ubc1c\uc131 \uace8\uc218\uc885 \ud504\ub85c\uadf8\ub7a8\uc740 \uc544\ubca0\ud06c\ub9c8\uc640 \uc2e4\ud0c0\uc140(cilta-cel)\uc774 \uac15\ub825\ud55c \uc0dd\uc874\uc728 \ub370\uc774\ud130\ub97c \ubc14\ud0d5\uc73c\ub85c 14.18%\uc758 CAGR\uc744 \uae30\ub85d\ud558\uba70 \uae09\uc99d\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ubc31\ud608\ubcd1 \ubd84\uc57c\ub294 2024\ub144 11\uc6d4 FDA\uac00 \uc131\uc778 ALL\uc5d0 \ub300\ud55c \uc624\ubca0\uc140(obe-cel)\uc744 55.3%\uc758 \uc644\uc804 \uad00\ud574\uc728\ub85c \uc2b9\uc778\ud558\uba74\uc11c \ubaa8\uba58\ud140\uc744 \uc5bb\uc5c8\uc2b5\ub2c8\ub2e4. \uc801\uc751\uc99d \ub2e4\uac01\ud654\ub294 \uc790\uac00\uba74\uc5ed \uc9c8\ud658(\uc608: \uc804\uc2e0\uc131 \ud64d\ubc18\uc131 \ub8e8\ud478\uc2a4) \ubc0f \uace0\ud615\uc554\uc73c\ub85c \ud655\uc7a5\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>5. \ucd5c\uc885 \uc0ac\uc6a9\uc790(End-User):<br \/>\n\ubcd1\uc6d0\uc740 \uc0ac\uc774\ud1a0\uce74\uc778 \ubc29\ucd9c \uc99d\ud6c4\uad70 \uad00\ub9ac\uc5d0 \ud544\uc218\uc801\uc778 \uc911\ud658\uc790\uc2e4 \ubc0f \ud608\uc561 \uc131\ubd84 \ucc44\uc9d1 \uc7a5\uce58\ub97c \uac16\ucd94\uace0 \uc788\uc5b4 2025\ub144 \uc804 \uc138\uacc4 \ub9e4\ucd9c\uc758 66.10%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \ud559\uc220 \uae30\uad00\uc740 \ubcf4\uc870\uae08 \uc9c0\uc6d0 \ud30c\uc77c\ub7ff \ud504\ub85c\uc81d\ud2b8 \ubc0f \ucc28\uc138\ub300 \ud50c\ub7ab\ud3fc \uc784\uc0c1 \uc2dc\ud5d8\uc744 \ubc18\uc601\ud558\uc5ec 15.20%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uba54\ub514\ucf00\uc5b4 NTAP \ud655\uc7a5 \ubc0f 2025\ub144 1\uc6d4\ubd80\ud130 \uc2dc\ud589\ub418\ub294 \uc0c8\ub85c\uc6b4 CPT \ucf54\ub4dc\uc5d0 \ub530\ub77c \uc9c0\uc5ed \uc13c\ud130\ub85c\uc758 \ud655\uc7a5\uc774 \uac00\uc18d\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p># \uc9c0\uc5ed \ubd84\uc11d<\/p>\n<p>1. \ubd81\ubbf8:<br \/>\n2025\ub144 \uc804 \uc138\uacc4 \ub9e4\ucd9c\uc758 52.10%\ub97c \ucc28\uc9c0\ud558\uba70, \ucd08\uae30 FDA \uc2b9\uc778, 311\uac1c\uc758 \uacf5\uc778 \uce58\ub8cc \uc2dc\uc124, \uac15\ub825\ud55c \ubbfc\uac04 \ubcf4\ud5d8 \uc801\uc6a9\uc744 \ubc18\uc601\ud569\ub2c8\ub2e4. 2025\ub144\ubd80\ud130 \uc2dc\ud589\ub418\ub294 \uc0c8\ub85c\uc6b4 CPT \uc2dc\uc220 \ucf54\ub4dc\ub294 \uccad\uad6c\ub97c \uac04\uc18c\ud654\ud558\uace0 \ud559\uc220 \ud5c8\ube0c \uc678\ubd80\uc5d0\uc11c\uc758 \ucc44\ud0dd\uc744 \uac00\uc18d\ud654\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc784\uc0c1\uc801\uc73c\ub85c \uc801\uaca9\ud55c \ubbf8\uad6d \ud658\uc790 5\uba85 \uc911 1\uba85\ub9cc\uc774 \ud604\uc7ac \uce58\ub8cc\ub97c \ubc1b\uace0 \uc788\uc5b4 \uc811\uadfc\uc131 \ubd88\uade0\ud615 \ubb38\uc81c\uac00 \uc874\uc7ac\ud569\ub2c8\ub2e4.<\/p>\n<p>2. \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591:<br \/>\n2031\ub144\uae4c\uc9c0 15.55%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc9c0\uc5ed\uc774 \ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc911\uad6d\uc740 2024\ub144 1\uc6d4\uae4c\uc9c0 300\uac1c \uc774\uc0c1\uc758 CAR-T \uc784\uc0c1 \uc2dc\ud5d8\uc744 \ub4f1\ub85d\ud558\uba70 \ubbf8\uad6d\uc744 \ucd94\uc6d4\ud588\uc2b5\ub2c8\ub2e4. \uc77c\ubcf8\uacfc \ud55c\uad6d\uc740 \uc804\ub7b5\uc801 \uc758\ub8cc \uc790\uc0b0\uc73c\ub85c\uc11c \uad6d\ub0b4 \uc81c\uc870\ub97c \ubaa9\ud45c\ub85c \uc2e0\uc18d \uc2ec\uc0ac \uacbd\ub85c\ub97c \ub3c4\uc785\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>3. \uc720\ub7fd:<br \/>\n\ubd84\uc0b0\ud615 \uc81c\uc870 \ubd84\uc57c\uc5d0\uc11c \ub3c5\ud2b9\ud55c \ud601\uc2e0 \uc6b0\uc704\ub97c \ubc14\ud0d5\uc73c\ub85c \uc0c1\ub2f9\ud55c \uc2dc\uc7a5 \uc810\uc720\uc728\uc744 \ubcf4\uc720\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ubca8\uae30\uc5d0\uc640 \uc2a4\ud398\uc778\uc5d0\uc11c 7\uc77c \ud604\uc7a5 \uc81c\uc870 \ud30c\uc77c\ub7ff \ud504\ub85c\uc81d\ud2b8\ub294 \uae30\uc220\uc801 \ud0c0\ub2f9\uc131\uacfc \uacbd\uc81c\uc801 \ud6a8\uc728\uc131\uc744 \uc785\uc99d\ud588\uc2b5\ub2c8\ub2e4. 2025\ub144 \uc608\uc815\ub41c \ud1b5\ud569 HTA(Health Technology Assessment) \uaddc\uce59\uc740 \ubcf4\ud5d8 \uc801\uc6a9\uc744 \uc870\ud654\uc2dc\ud0ac \uc218 \uc788\uc9c0\ub9cc, \uad6d\uac00\ubcc4 \uac00\uaca9 \ud611\uc0c1\uc740 \uc5ec\uc804\ud788 \ucc44\ud0dd\uc744 \ubd84\uc5f4\uc2dc\ud0a4\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p># \uacbd\uc7c1 \ud658\uacbd<\/p>\n<p>CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc0b0\uc5c5\uc740 \uc911\uac04 \uc815\ub3c4\uc758 \uc9d1\uc911\ub3c4\ub97c \ubcf4\uc774\uba70, \uc0c1\uc704 5\uac1c \uae30\uc5c5\uc774 2024\ub144 \uc804 \uc138\uacc4 \ub9e4\ucd9c\uc5d0\uc11c \uc0c1\ub2f9\ud55c \ube44\uc911\uc744 \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \ub178\ubc14\ud2f0\uc2a4(Novartis)\ub294 \ud0b4\ub9ac\uc544(Kymriah)\ub85c \ucd08\uae30 \uae30\uc900\uc744 \uc138\uc6e0\uc9c0\ub9cc, \ud604\uc7ac\ub294 \uace0\ud615\uc554\uc744 \uc704\ud55c \ucc28\uc138\ub300 \uc790\uc0b0\uc5d0 \uc7ac\ud22c\uc790\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uae38\ub9ac\uc5b4\ub4dc(Gilead)\uc758 \uce74\uc774\ud2b8(Kite) \uc0ac\uc5c5\ubd80\ub294 LBCL \ubc0f \uc678\ud22c\uc138\ud3ec \ub9bc\ud504\uc885 \ubd84\uc57c\uc5d0\uc11c \ub9ac\ub354\uc2ed\uc744 \ud655\ubcf4\ud558\uae30 \uc704\ud574 2026\ub144\uae4c\uc9c0 \uc804 \uc138\uacc4 \uc0dd\uc0b0 \ub2a5\ub825\uc744 4\ubc30\ub85c \ub298\ub9b4 \uacc4\ud68d\uc785\ub2c8\ub2e4. \ube0c\ub9ac\uc2a4\ud1a8-\ub9c8\uc774\uc5b4\uc2a4 \uc2a4\ud045(Bristol-Myers Squibb)\uc740 \uc544\ubca0\ud06c\ub9c8(Abecma)\uc758 \uc870\uae30 \uce58\ub8cc \ub77c\uc778 \ub2e4\ubc1c\uc131 \uace8\uc218\uc885 \uc2b9\uc778\uc744 \ud65c\uc6a9\ud558\uace0 \uc788\uc73c\uba70, \ub9c8\uc9c4 \uac1c\uc120\uc744 \uc704\ud574 \uc0dd\uc0b0 \uc790\ub3d9\ud654\ub97c \ucd94\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc804\ub7b5\uc801 \ud30c\ud2b8\ub108\uc2ed\uc740 \ud601\uc2e0\uc744 \uc704\ud55c \uc8fc\uc694 \uacbd\ub85c\ub85c \ub0a8\uc544 \uc788\uc2b5\ub2c8\ub2e4. \uc560\ube0c\ube44(AbbVie)\ub294 \ud658\uc790 \uccb4\ub0b4\uc5d0\uc11c \ubcc0\ud615\ub41c T-\uc138\ud3ec\ub97c \uc0dd\uc131\ud560 \uc218 \uc788\ub294 in-situ CAR-T \ubca1\ud130\ub97c \uc704\ud574 \uc6b0\ubaa8\uc790 \ubc14\uc774\uc624\ud30c\ub9c8(Umoja Biopharma)\uc5d0 \ucd5c\ub300 14.4\uc5b5 \ub2ec\ub7ec\ub97c \ud22c\uc790\ud588\uc2b5\ub2c8\ub2e4. \ubc14\uc774\uc624\uc5d4\ud14d(BioNTech)\uc740 mRNA \ubc31\uc2e0 \uc678\uc5d0 \ub2e4\uac01\ud654\ub97c \uc704\ud574 \uc624\ud1a0\ub8e8\uc2a4(Autolus)\uc5d0 2\uc5b5 \ub2ec\ub7ec\ub97c \ud22c\uc790\ud558\uc5ec AUTO1\/22\ub97c \uacf5\ub3d9 \uc0c1\uc5c5\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc81c\uc870\ub294 \ud575\uc2ec \uacbd\uc7c1 \ubd84\uc57c\ub85c \ub0a8\uc544 \uc788\uc73c\uba70, \uc54c\ub85c\uc820(Allogene)\uc740 \ube44\uc6a9 \uc808\uac10 \ubc0f \uac70\ubd80 \ubc18\uc751 \uc704\ud5d8 \uac10\uc18c\ub97c \uc704\ud574 TALEN \ud3b8\uc9d1 \uc138\ud3ec\ub97c \uc774\uc6a9\ud55c \uc0c1\uc5c5 \uaddc\ubaa8\uc758 \ub3d9\uc885\uc720\ub798 \uc0dd\uc0b0 \uc2dc\uc124\uc744 \uac74\uc124 \uc911\uc785\ub2c8\ub2e4.<\/p>\n<p># \ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5<\/p>\n<p>*   2025\ub144 1\uc6d4: \uce74\uace0 \ud14c\ub77c\ud4e8\ud2f1\uc2a4(CARGO Therapeutics)\ub294 \ud53c\ub9ac\uc140(firi-cel) \uc784\uc0c1 2\uc0c1\uc5d0\uc11c 71\uba85\uc758 \ud658\uc790\uc5d0\uac8c \ud22c\uc5ec\ud588\uc73c\uba70, \uba74\uc5ed \uac70\ubd80 \ubc18\uc751\uc744 \uc5b5\uc81c\ud558\uae30 \uc704\ud55c \ub3d9\uc885\uc720\ub798 \ud50c\ub7ab\ud3fc\uc744 \uacf5\uac1c\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2024\ub144 4\uc6d4: ASCO \ub370\uc774\ud130\uc5d0 \ub530\ub974\uba74 \uc608\uc2a4\uce74\ub974\ud0c0(Yescarta)\ub294 CNS \ub9bc\ud504\uc885\uc5d0\uc11c 94.4%\uc758 \uac1d\uad00\uc801 \ubc18\uc751\ub960\uc744 \ub2ec\uc131\ud588\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf4\uace0\uc11c \uc694\uc57d: CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5 \ubd84\uc11d<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud558\uba70, \uc2dc\uc7a5 \uc815\uc758, \uc5f0\uad6c \ubc29\ubc95\ub860, \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21, \uc8fc\uc694 \ub3d9\ub825 \ubc0f \uc81c\uc57d \uc694\uc778, \uc138\ubd84\ud654, \uacbd\uc7c1 \ud658\uacbd \ubc0f \ubbf8\ub798 \uc804\ub9dd\uc744 \ub2e4\ub8f9\ub2c8\ub2e4.<\/p>\n<p>1. \uc2dc\uc7a5 \uc815\uc758 \ubc0f \uc5f0\uad6c \ubc94\uc704<br \/>\nCAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 \ud608\uc561\uc554 \ub610\ub294 \uace0\ud615\uc554 \uce58\ub8cc\ub97c \uc704\ud574 \uc0c1\uc5c5\uc801\uc73c\ub85c \uc2b9\uc778\ub41c \uc720\uc804\uc790 \ubcc0\ud615 \uc790\uac00\uc720\ub798(autologous) \ubc0f \ub3d9\uc885\uc720\ub798(allogeneic) T-\uc138\ud3ec \uc81c\ud488\uc5d0\uc11c \ubc1c\uc0dd\ud558\ub294 \uc218\uc775\uc744 \uae30\uc900\uc73c\ub85c \uc815\uc758\ub429\ub2c8\ub2e4. \ubcf8 \uc5f0\uad6c\ub294 \ub3d9\ubc18 \uc9c4\ub2e8, \ube44-CAR \uc785\uc591 \uc138\ud3ec \uce58\ub8cc\uc81c, \ubcd1\uc6d0 \uc2dc\uc220 \ub9c8\ud06c\uc5c5, \uadf8\ub9ac\uace0 \uc784\uc0c1\uc2dc\ud5d8 \ub2e8\uacc4\uc758 CAR-NK \ub610\ub294 \u03b3\u03b4-T \uc81c\ud488\uc740 \uc81c\uc678\ud569\ub2c8\ub2e4.<\/p>\n<p>2. \uc5f0\uad6c \ubc29\ubc95\ub860<br \/>\n\ubcf8 \uc5f0\uad6c\ub294 \ud608\uc561\ud559\uc790, \uc9c0\ubd88\uc790, \uc81c\uc870 \ucc45\uc784\uc790\ub4e4\uacfc\uc758 \uc2ec\uce35 \uc778\ud130\ubdf0\ub97c \ud3ec\ud568\ud55c 1\ucc28 \uc5f0\uad6c\uc640 \uc885\uc591\ud559 \ud30c\uc774\ud504\ub77c\uc778, FDA, EMA, PMDA\uc758 \ubb38\uc11c, \ubbf8\uad6d \uc554 \ud559\ud68c \uc790\ub8cc, ClinicalTrials.gov \ub370\uc774\ud130 \ub4f1 \uad11\ubc94\uc704\ud55c 2\ucc28 \uc5f0\uad6c\ub97c \ud1b5\ud574 \uc218\ud589\ub418\uc5c8\uc2b5\ub2c8\ub2e4. \uc2dc\uc7a5 \uaddc\ubaa8 \uc0b0\uc815 \ubc0f \uc608\uce21\uc740 \uc7ac\ubc1c\uc131 B-\uc138\ud3ec \uc545\uc131\uc885\uc591 \ubc1c\uc0dd\ub960, \uc801\uaca9 \ud658\uc790 \ube44\uc728, \uc758\ub8b0\uc728, \uce58\ub8cc \uc811\uadfc\uc131\uc744 \uacf1\ud558\ub294 \ud558\ud5a5\uc2dd(top-down) \uc811\uadfc \ubc29\uc2dd\uacfc \uacf5\uae09\uc5c5\uccb4 \uc9d1\uacc4 \ubc0f \ubcd1\uc6d0 \uccad\uad6c \ub9c8\uc2a4\ud130 \ud655\uc778\uc744 \ud1b5\ud55c \uc0c1\ud5a5\uc2dd(bottom-up) \uac80\uc99d\uc744 \uacb0\ud569\ud558\uc5ec \uc774\ub8e8\uc5b4\uc84c\uc2b5\ub2c8\ub2e4. \ub370\uc774\ud130\ub294 \ub9e4\ub144 \uc5c5\ub370\uc774\ud2b8\ub418\uba70, \uc5c4\uaca9\ud55c \uac80\uc99d \uacfc\uc815\uc744 \uac70\uccd0 \uc2e0\ub8b0\uc131 \uc788\ub294 \uae30\uc900\uc120\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n<p>3. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21<br \/>\nCAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2026\ub144 47.7\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\uc5d0\uc11c 2031\ub144\uae4c\uc9c0 90.3\uc5b5 \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \ud2b9\ud788 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 \uc784\uc0c1\uc2dc\ud5d8 \ud65c\ub3d9 \ud655\ub300\uc640 \uad6d\ub0b4 \uc81c\uc870 \uc2dc\uc124 \uad6c\ucd95\uc5d0 \ud798\uc785\uc5b4 15.55%\uc758 \uac00\uc7a5 \ube60\ub978 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR)\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p>4. \uc2dc\uc7a5 \ub3d9\ub825<br \/>\n\uc2dc\uc7a5\uc758 \uc131\uc7a5\uc744 \uacac\uc778\ud558\ub294 \uc8fc\uc694 \uc694\uc778\ub4e4\uc740 \ub2e4\uc74c\uacfc \uac19\uc2b5\ub2c8\ub2e4.<br \/>\n*   FDA \uc2b9\uc778 \uac00\uc18d\ud654: 2\ucc28 LBCL(\uac70\ub300 B\uc138\ud3ec \ub9bc\ud504\uc885)\uc5d0 \ub300\ud55c FDA \uc2b9\uc778\uc774 \ucd08\uae30 \uce58\ub8cc \ub2e8\uacc4\uc5d0\uc11c\uc758 \ucc44\ud0dd\uc744 \uac00\uc18d\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ubd84\uc0b0\ud615 \ud604\uc7a5 \uc81c\uc870: \uc720\ub7fd \ub0b4 \ubd84\uc0b0\ud615 \ud604\uc7a5 \uc81c\uc870(Point-of-Care Manufacturing)\ub294 &#8216;\uc815\ub9e5-\uc815\ub9e5(vein-to-vein)&#8217; \uc2dc\uac04\uc744 \ub2e8\ucd95\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   \uc554 \ubd80\ub2f4 \uc99d\uac00: \uc804 \uc138\uacc4\uc801\uc73c\ub85c \uc554 \ubc1c\uc0dd\ub960\uc774 \uc99d\uac00\ud558\uace0 \uc788\uc5b4 \uce58\ub8cc\uc81c \uc218\uc694\uac00 \ub298\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ub3d9\uc885\uc720\ub798 &#8220;\uae30\uc131\ud488(Off-the-Shelf)&#8221; \ud30c\uc774\ud504\ub77c\uc778: \ub3d9\uc885\uc720\ub798 \uc81c\ud488 \uac1c\ubc1c\uc740 \uc81c\uc870 \uc6d0\uac00\ub97c \ub0ae\ucd94\ub294 \ub370 \uae30\uc5ec\ud569\ub2c8\ub2e4.<br \/>\n*   \ud22c\uc790 \ubc0f R&#038;D \ud655\ub300: CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc744 \uc704\ud55c \ud22c\uc790 \ubc0f \uc5f0\uad6c \uac1c\ubc1c\uc774 \ud65c\ubc1c\ud788 \uc774\ub8e8\uc5b4\uc9c0\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uba54\ub514\ucf00\uc5b4 NTAP \ud655\uc7a5: \uc9c0\uc5ed \uc885\uc591\ud559 \uc13c\ud130\ub85c\uc758 \uba54\ub514\ucf00\uc5b4 NTAP(\uc2e0\uae30\uc220 \ucd94\uac00 \uc9c0\ubd88) \ud655\uc7a5\uc740 \ud658\uc790 \uc811\uadfc\uc131\uc744 \ub192\uc785\ub2c8\ub2e4.<\/p>\n<p>5. \uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778<br \/>\n\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\ub4e4\ub3c4 \uc874\uc7ac\ud569\ub2c8\ub2e4.<br \/>\n*   \ub192\uc740 \uac1c\ubc1c \ube44\uc6a9: CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc5d0\ub294 \ub9c9\ub300\ud55c \ube44\uc6a9\uc774 \uc18c\uc694\ub429\ub2c8\ub2e4.<br \/>\n*   \ubca1\ud130 GMP \uc6a9\ub7c9 \ubcd1\ubaa9 \ud604\uc0c1: \ubca1\ud130 GMP(\uc6b0\uc218 \uc758\uc57d\ud488 \uc81c\uc870 \ubc0f \ud488\uc9c8 \uad00\ub9ac \uae30\uc900) \uc6a9\ub7c9 \ubd80\uc871\uc740 \ub9ac\ub4dc \ud0c0\uc784\uc744 \uc99d\uac00\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   \uc81c\ud55c\uc801\uc778 \ud658\uc790 \uc801\uaca9\uc131: \uce58\ub8cc \ub300\uc0c1 \ud658\uc790\uad70\uc774 \uc81c\ud55c\uc801\uc785\ub2c8\ub2e4.<br \/>\n*   \uc2ec\uac01\ud55c \ubd80\uc791\uc6a9 \uac00\ub2a5\uc131: \uc7a0\uc7ac\uc801\uc778 \uc2ec\uac01\ud55c \ubd80\uc791\uc6a9 \ubc1c\uc0dd \uac00\ub2a5\uc131\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>6. \uc2dc\uc7a5 \uc138\ubd84\ud654<br \/>\n\uc2dc\uc7a5\uc740 \ud45c\uc801 \ud56d\uc6d0(CD19, BCMA \ub4f1), \uc138\ud3ec \uacf5\uae09\uc6d0(\uc790\uac00\uc720\ub798, \ub3d9\uc885\uc720\ub798), \uc2b9\uc778\ub41c \uc81c\ud488(Abecma, Kymriah \ub4f1), \uc801\uc751\uc99d(\ubc31\ud608\ubcd1, \ub9bc\ud504\uc885, \ub2e4\ubc1c\uc131 \uace8\uc218\uc885 \ub4f1), \ucd5c\uc885 \uc0ac\uc6a9\uc790(\ubcd1\uc6d0, \uc554 \uce58\ub8cc \uc13c\ud130 \ub4f1), \uadf8\ub9ac\uace0 \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8) \ub4f1 \ub2e4\uc591\ud55c \uae30\uc900\uc5d0 \ub530\ub77c \uc138\ubd84\ud654\ub418\uc5b4 \ubd84\uc11d\ub429\ub2c8\ub2e4.<\/p>\n<p>7. \uacbd\uc7c1 \ud658\uacbd<br \/>\nNovartis AG, Gilead Sciences Inc. (Kite Pharma), Bristol-Myers Squibb Co., Johnson &#038; Johnson \/ Legend Biotech \ub4f1 \ub2e4\uc218\uc758 \uc8fc\uc694 \uae30\uc5c5\ub4e4\uc774 \uae00\ub85c\ubc8c CAR T-\uc138\ud3ec \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc5d0\uc11c \uacbd\uc7c1\ud558\uace0 \uc788\uc73c\uba70, \uc2dc\uc7a5 \uc9d1\uc911\ub3c4 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d\uc774 \ud3ec\ud568\ub429\ub2c8\ub2e4.<\/p>\n<p>8. \uc8fc\uc694 \ud1b5\ucc30 \ubc0f \ubbf8\ub798 \uc804\ub9dd<br \/>\n\ub3d9\uc885\uc720\ub798 &#8220;\uae30\uc131\ud488&#8221; CAR T-\uc138\ud3ec \uc81c\ud488\uc740 \ud22c\uc5ec \ube44\uc6a9\uc744 \ucd5c\ub300 95% \uc808\uac10\ud558\uace0 \uc989\uac01\uc801\uc778 \uce58\ub8cc\ub97c \uac00\ub2a5\ud558\uac8c \ud558\uc5ec \uc9c0\ubd88\uc790\uc758 \ubd80\ub2f4\uc744 \uc904\uc774\uace0 \uc811\uadfc\uc131\uc744 \ud5a5\uc0c1\uc2dc\ud0a4\ub294 \uc911\uc694\ud55c \uc5ed\ud560\uc744 \ud560 \uac83\uc785\ub2c8\ub2e4. \ub610\ud55c, 2025\ub144 1\uc6d4\ubd80\ud130 \uc2dc\ud589\ub418\ub294 \uc0c8\ub85c\uc6b4 CPT(Current Procedural Terminology) \ucf54\ub4dc\ub294 \uc9c0\uc5ed \uc885\uc591\ud559 \uc13c\ud130\uc758 \uccad\uad6c \uc808\ucc28\ub97c \uac04\uc18c\ud654\ud558\uc5ec \ub300\ud615 \ud559\uc220 \ubcd1\uc6d0 \uc678\uc758 \ud658\uc790 \uc811\uadfc\uc131\uc744 \ud655\ub300\ud560 \uac83\uc73c\ub85c \uae30\ub300\ub429\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-58761","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/58761"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=58761"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/58761\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=58761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=58761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=58761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}